Dataset Information
An amylin analog used as a challenge test for Alzheimer's disease.
Ontology highlight
ABSTRACT: Introduction
Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans.Methods
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.Results
None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects.Discussion
Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.
SUBMITTER: Zhu H
PROVIDER: S-EPMC5424531 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Publications
An amylin analog used as a challenge test for Alzheimer's disease.
Alzheimer's & dementia (New York, N. Y.) 20170101 1
<h4>Introduction</h4>Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans.<h4>Methods</h4>We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.<h4>Results</h4>None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challeng ...[more]